Loading clinical trials...
Loading clinical trials...
INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group
Conditions
Interventions
Depatuxizumab mafodotin
Temozolomide
+1 more
Locations
102
United States
Lucile Packard Children's Hosp /ID# 153678
Palo Alto, California, United States
Children's Hospital Colorado /ID# 153677
Aurora, Colorado, United States
Univ of Colorado Cancer Center /ID# 134882
Aurora, Colorado, United States
Sarah Cannon Research Institute at HealthONE - Denver /ID# 141798
Denver, Colorado, United States
Rush University Medical Center /ID# 137542
Chicago, Illinois, United States
Dana-Farber Cancer Institute /ID# 154210
Boston, Massachusetts, United States
Start Date
February 17, 2015
Primary Completion Date
June 24, 2019
Completion Date
June 24, 2019
Last Updated
May 22, 2020
NCT05969860
NCT02800486
NCT05789394
NCT05839379
NCT00083512
NCT05283330
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions